

Colorado HB 19-1131 Disclosure

NEXLETOL[®] (bempedoic acid) tablets, NEXLIZET[®] (bempedoic acid and ezetimibe) tablets, and ENBUMYST[™] (bumetanide nasal spray).

The following information is provided to Colorado prescribers by Esperion Therapeutics, Inc. in accordance with Colorado House Bill 19-1131.

The pricing information below reflects Esperion's Wholesale Acquisition Costs (WAC) for the Esperion products and may not represent actual transactional prices. The price consumers pay for the product may vary from the prices listed below depending upon the availability of discounts and how the consumer purchases the product.

WAC for Esperion Products

Products	NDC	Dosage Form and Strength	WAC
NEXLETOL [®] (bempedoic acid) tablets	72426-118-03	Bottle of 30	\$432.68
NEXLIZET [®] (bempedoic acid and ezetimibe) tablets	72426-818-03	Bottle of 30	\$432.68
ENBUMYST [™] (bumetanide nasal spray)	84388-005-12	12-Count Package	\$1,197.00

Source: Analysource[®] Premiere Drug Pricing Services.

Colorado law requires a manufacturer to provide the names of at least three generic prescriptions drugs that are in the same therapeutic class as Esperion's products. Based on the definition in Colorado House Bill 19-1131: "Therapeutic Class" means a group of similar drugs that have the same or similar mechanisms of action and are used to treat a specific condition.

- **Currently, there are no other generic prescription drugs in the same therapeutic class as NEXLETOL[®] and NEXLIZET[®]**
- **The following generic prescriptions drugs are in the same therapeutic class as ENBUMYST[™]: bumetanide injection, bumetanide oral tablet, and furosemide oral tablet.**
- Esperion will update this disclosure form should generic drugs become available within the same therapeutic class as NEXLETOL[®] and NEXLIZET[®].

This information—including product information—is intended only for residents of the United States. The products discussed herein may have different labeling in different countries.

Effective as of July 2026

All trademarks and trade names are the property of their respective owners.
© 2026 Esperion Therapeutics, Inc. All rights reserved.